Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.
Metavention, Inc., established in 2012 and headquartered in Dover, Delaware, specializes in the development of trans-catheter devices aimed at modulating sympathetic nervous system activity. These innovative devices address the issues of over-active sympathetic nerves that contribute to elevated glucose levels and abnormal liver function. By employing standard interventional vascular techniques, Metavention provides healthcare professionals with a novel tool for diagnosing and treating patients with Type 2 diabetes. The company focuses on enhancing treatment options for this condition, ultimately improving patient outcomes.
SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies.
SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies.
SpecificiT’s unique approach is centered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient.
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology. The company focuses on heterogeneous genetic disorders that primarily manifest in bone dysfunction. In depth understanding of disease mechanism will allow PreciThera’s targeted strategies to meaningfully impact both the skeletal symptoms as well as the extraskeletal issues found in these patients.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
DalCor Pharmaceuticals specializes in precision medicine aimed at treating cardiovascular diseases by tailoring therapies to individual patients based on their genetic profiles. The company's primary product, dalcetrapib, is a cholesterol ester transfer protein inhibitor designed to mitigate residual cardiovascular risk in patients with a specific ADCY9 genetic profile. This approach is supported by pharmacogenomic research indicating that patients with acute coronary syndrome who possess a particular genetic variant experience a significant reduction in cardiovascular events when treated with dalcetrapib compared to placebo. Founded in 2015, DalCor has established its headquarters in Montreal, Canada, with additional offices in Sarasota, Florida; Zug, Switzerland; and Leatherhead, United Kingdom. The company has secured exclusive worldwide rights to dalcetrapib and the associated ADCY9 genetic marker from Roche, allowing it to focus on enhancing treatment outcomes for genetically targeted patients.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Liphorus Pharmaceuticals Inc. is a Montreal-based company founded in 2014 that focuses on the development of innovative pharmaceuticals. The company specializes in creating small molecules and therapeutic antibodies aimed at targeting PCSK9, a key protein involved in regulating cholesterol levels. Liphorus's products are designed for the treatment of hypercholesterolemia, helping patients to effectively lower LDL, or "bad" cholesterol levels, through oral administration. By leveraging advanced biotechnological techniques, Liphorus Pharmaceuticals aims to provide enhanced solutions for managing cholesterol-related health issues.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
TheraVida, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products for urological disorders and central nervous system conditions. The company specializes in treatments for overactive bladder (OAB) and urge urinary incontinence, with its flagship product, Tolenix, which combines tolterodine, a muscarinic antagonist, with pilocarpine, a muscarinic agonist, to address both OAB and dry mouth side effects. TheraVida’s innovative drug platform aims to enhance the tolerability of existing anti-muscarinic therapies while maintaining their efficacy. Founded in 2005, TheraVida is headquartered in San Mateo, California.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
TheraVida, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products for urological disorders and central nervous system conditions. The company specializes in treatments for overactive bladder (OAB) and urge urinary incontinence, with its flagship product, Tolenix, which combines tolterodine, a muscarinic antagonist, with pilocarpine, a muscarinic agonist, to address both OAB and dry mouth side effects. TheraVida’s innovative drug platform aims to enhance the tolerability of existing anti-muscarinic therapies while maintaining their efficacy. Founded in 2005, TheraVida is headquartered in San Mateo, California.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Neomend, Inc., a biomedical device company, engages in the development and commercialization of surgical wound healing products. Its platform technology, Pro/PEG, is a bioadhesive polymer hydrogel. NeoMend engages in commercialization of the combination wound sealant and adhesion barrier product that can be delivered during minimally invasive/laparoscopic procedures. Neomend, Inc. was founded in 1999 and is based in Irvine, California.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
NovoStent Corporation
Venture Round in 2009
NovoStent Corporation, a medical device company that has developed a novel "anchored" helical stent technology to provide a wide range of vascular therapies.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
Axikin Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused exclusively on the development and commercialization of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. Axikin was spun out from Actimis Pharmaceuticals, in June 2008.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Pacira BioSciences Inc. is a pharmaceutical company based in San Diego, California, focused on developing and manufacturing non-opioid pain management and regenerative health solutions. Founded in 1989, the company offers three main products: EXPAREL, a long-acting local analgesic designed for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis management; and iovera, a handheld device that provides immediate, drug-free pain relief through controlled cold therapy targeting specific nerves. Pacira BioSciences aims to enhance treatment outcomes for healthcare practitioners and their patients by providing effective alternatives to opioid-based pain management.
ISTA Pharmaceuticals is a commercial-stage multispecialty pharmaceutical company. It discovers, develops, and markets remedies for diseases and conditions of the eye in the United States. The company offers products to treat allergies and serious diseases of the eye; and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. The company’s marketed products comprise of BROMDAY, a bromfenac ophthalmic solution for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extractions; BEPREVE, a bepotastine besilate ophthalmic solution for ocular itching associated with allergic conjunctivitis; ISTALOL, a timolol maleate ophthalmic solution for the treatment of glaucoma; and VITRASE, a hyaluronidase injection for use as a spreading agent. Its products under development include OTC artificial tear products to treat dry eye and other ocular conditions; PROLENSA, a bromfenac ophthalmic solution for the treatment of postoperative inflammation and reduction of ocular pain after cataract extractions; T-PRED for steroid responsive inflammation; BEPOMAX and BEPOSONE nasal sprays for treating allergic rhinitis; and Bromfenac Adjunct for age-related macular degeneration. In addition, the company develops iganidipine to enhance ocular nerve blood flow; latanoprost, a prostaglandin for the treatment of glaucoma; and ecabet sodium for the treatment of dry eye. ISTA Pharmaceuticals sells its products to drug wholesalers; retailers and distributors such as chain drug stores, hospitals, clinics, and government agencies; and managed healthcare providers including health maintenance organizations and other institutions. ISTA Pharmaceuticals was founded in 1992 and is headquartered in Irvine, California. As of June 5, 2012, ISTA Pharmaceuticals operates as a subsidiary of Bausch & Lomb Incorporated.
Altor BioScience Corporation, founded in 2002 and based in Miramar, Florida, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of immunotherapeutic agents aimed at treating cancer, viral infections, and autoimmune diseases. The company’s product portfolio includes several innovative candidates such as ALT-801, a T-cell receptor-targeted treatment for cancer, and ALT-803, an IL-15 superagonist for solid tumors and metastatic melanoma. Altor also develops novel monoclonal antibodies and fusion proteins, targeting conditions such as acute respiratory distress syndrome and non-small cell lung cancer. Additionally, the company offers STAR Fusion and STAR Multimer Reagents, which are utilized for the diagnosis and targeting of cancer and viral infections, as well as for research in vaccine development. Altor BioScience's focus on the immunostimulatory properties of cytokines like IL-15 and IL-2 underlines its commitment to enhancing the immune response against diseases.
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.
Asteres Inc. is a company specializing in pharmacy automation technology, founded in 2003 and based in San Diego, California. It develops and installs kiosks and lockers that facilitate the pickup of prescriptions and healthcare products at various locations, including retail stores, hospitals, corporate worksites, and military bases. Asteres is known for its ScriptCenter system, which functions similarly to an ATM, allowing consumers to retrieve and pay for their prescriptions outside of regular pharmacy hours or without waiting in line. This innovation not only extends pharmacy service hours without requiring additional staff but also enhances customer convenience, encouraging shoppers to remain in-store. Asteres further supports its products with integration of IT, pharmacy management, and payment systems, along with marketing and maintenance services. The company's expertise in healthcare automation stems from a management team with significant experience in retail pharmacy and healthcare systems.
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
Asteres Inc. is a company specializing in pharmacy automation technology, founded in 2003 and based in San Diego, California. It develops and installs kiosks and lockers that facilitate the pickup of prescriptions and healthcare products at various locations, including retail stores, hospitals, corporate worksites, and military bases. Asteres is known for its ScriptCenter system, which functions similarly to an ATM, allowing consumers to retrieve and pay for their prescriptions outside of regular pharmacy hours or without waiting in line. This innovation not only extends pharmacy service hours without requiring additional staff but also enhances customer convenience, encouraging shoppers to remain in-store. Asteres further supports its products with integration of IT, pharmacy management, and payment systems, along with marketing and maintenance services. The company's expertise in healthcare automation stems from a management team with significant experience in retail pharmacy and healthcare systems.
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.
Neomend, Inc., a biomedical device company, engages in the development and commercialization of surgical wound healing products. Its platform technology, Pro/PEG, is a bioadhesive polymer hydrogel. NeoMend engages in commercialization of the combination wound sealant and adhesion barrier product that can be delivered during minimally invasive/laparoscopic procedures. Neomend, Inc. was founded in 1999 and is based in Irvine, California.
Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.
Xytis is a biopharmaceutical company focusing on the discovery and development of innovative CNS drug candidates. The company is privately held and was created in Jan 2006 by the merger of Xytis Pharmaceuticals Ltd. (UK) and Remergent, Inc. (USA). The company received funding from Sanderling Ventures, Atlas Venture, CDC Entreprises Innovation, and Ventech. Xytis Inc. is assembling a pipeline of innovative compounds with validated mechanisms of action, addressing major unmet clinical needs in CNS fields such as Schizophrenia, Traumatic Brain Injury, Depression, Anxiety, or Insomnia. The company has two clinical stage compounds in development and operates from the USA, UK and Switzerland.
Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.
Tomophase Corporation, an opto-medical device company, develops minimally invasive optical coherence tomography tissue imaging devices. It provides endoscopic tissue imaging systems; and investigational airway and pulmonary systems. The company was founded in 2003 and is based in Burlington, Massachusetts.
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.
Alteer
Venture Round in 2005
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.
Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.
Asteres Inc. is a company specializing in pharmacy automation technology, founded in 2003 and based in San Diego, California. It develops and installs kiosks and lockers that facilitate the pickup of prescriptions and healthcare products at various locations, including retail stores, hospitals, corporate worksites, and military bases. Asteres is known for its ScriptCenter system, which functions similarly to an ATM, allowing consumers to retrieve and pay for their prescriptions outside of regular pharmacy hours or without waiting in line. This innovation not only extends pharmacy service hours without requiring additional staff but also enhances customer convenience, encouraging shoppers to remain in-store. Asteres further supports its products with integration of IT, pharmacy management, and payment systems, along with marketing and maintenance services. The company's expertise in healthcare automation stems from a management team with significant experience in retail pharmacy and healthcare systems.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Artielle ImmunoTherapeutics, Inc. is a biopharmaceutical company based in Tigard, Oregon, that develops biologic drugs aimed at treating inflammatory and degenerative diseases. Founded in 2004, the company specializes in therapies for neuro-inflammatory conditions such as multiple sclerosis, optic neuritis, and stroke, as well as autoimmune diseases like rheumatoid arthritis, celiac disease, and type 1 diabetes. Artielle's primary focus includes the development of recombinant T-cell receptor ligands (RTLs), specifically RTL1000 for multiple sclerosis, which target the CD74 receptor on monocytes to inhibit the action of macrophage migration inhibitory factor. Through its innovative platform, Artielle aims to address significant unmet medical needs in the treatment of various debilitating conditions.
Zapaq, Inc. is a privately held biopharmaceutical company focused on discovering an developing therapeutics that target aspartic proteases, a group of enzymes central to a variety of human diseases, including Alzheimer's. The company is headquartered in Waltham, MA and has research and development operations in Oklahoma City, OK.
CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.
Kadmus Pharmaceuticals
Series A in 2004
Kadmus Pharmaceuticals, Inc., a biopharmaceutical company, commercially exploits endocannabinoid pathways to develop therapeutics. Endocannabinoids are naturally occurring signaling molecules, whose functions include regulating mood, pain, and metabolism. It offers a portfolio of compounds with activity against a range of disorders targeting CNS conditions, metabolic disorders, neuropathic pain, and obesity. The company develops products for various conditions through the inhibition of endocannabinoid degradation and activation of endocannabinoid related pathways and peripheral cannabinoid receptors. It operates in the United States, Canada, and Europe. Kadmus Pharmaceuticals, Inc. was founded in 1998 and is based in Irvine, California.
Asteres Inc. is a company specializing in pharmacy automation technology, founded in 2003 and based in San Diego, California. It develops and installs kiosks and lockers that facilitate the pickup of prescriptions and healthcare products at various locations, including retail stores, hospitals, corporate worksites, and military bases. Asteres is known for its ScriptCenter system, which functions similarly to an ATM, allowing consumers to retrieve and pay for their prescriptions outside of regular pharmacy hours or without waiting in line. This innovation not only extends pharmacy service hours without requiring additional staff but also enhances customer convenience, encouraging shoppers to remain in-store. Asteres further supports its products with integration of IT, pharmacy management, and payment systems, along with marketing and maintenance services. The company's expertise in healthcare automation stems from a management team with significant experience in retail pharmacy and healthcare systems.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.
CyThera, Inc., headquartered in San Diego, CA, is a biotechnology company focused on developing cell replacement therapies for the treatment of human degenerative diseases. The company's proprietary technology platform enables the expansion and proliferation of functional human cells that can be used to treat human degenerative disease.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.
Alteer
Venture Round in 2002
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.
Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the discovery and development of novel vaccines and treatments for infectious diseases. The company markets HEPLISAV-B, an adjuvanted vaccine for the prevention of hepatitis B infection in adults. Dynavax utilizes its unique Toll-like Receptor Immune Modulation Platform to stimulate the body's immune responses, which is integral to its product development. In addition to its commercial offerings, Dynavax has an active immuno-oncology portfolio, featuring candidates such as SD-101 and DV281. The company is engaged in various research collaborations aimed at developing COVID-19 vaccines, partnering with organizations like Clover Biopharmaceuticals, the University of Queensland, and CEPI. These partnerships reflect Dynavax's commitment to addressing urgent health challenges through innovative vaccine solutions. Founded in 1996, Dynavax has evolved from its original name, Double Helix Corporation, to focus on enhancing immune responses for better disease prevention and treatment.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of products for the diagnosis and treatment of cardio-renal diseases. Discovery Therapeutics' product pipeline includes adenosine agonists and antagonists for the diagnosis and treatment of cardiovascular disease and leukotriene synthesis inhibitors for the treatment of chronic renal disease. In addition the company has license agreements with strategic partners involving novel late stage products for the treatment of Parkinson's disease and diagnosis of coronary artery disease.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.
BioSpace, Inc. operates an online platform that serves as a community for life science professionals, offering industry news and career opportunities. Through its website, BioSpace.com, the company provides a job board alongside daily feeds of biotechnology news and features that facilitate connections among recruiters, job seekers, and industry experts. By fostering communication and collaboration among business and scientific leaders, BioSpace enhances recruitment and professional development within the biotechnology, pharmaceuticals, medical devices, diagnostics, clinical research, academic, and biomedical sectors. Additionally, the company organizes career events aimed at life science recruiting professionals across the United States and Canada. Headquartered in Englewood, Colorado, with an office in San Francisco, California, BioSpace is recognized as a key resource for industry news and career advancement.
CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.
Net32, Inc. operates a business-to-business online comparison shopping marketplace specifically designed for the dental industry. The platform allows dentists to efficiently purchase a wide range of dental supplies, equipment, and services, including anesthetic products, infection control items, orthodontic products, and laboratory supplies. By streamlining the purchasing process, Net32 enables dental practices to reduce their overhead costs, which can significantly enhance profitability. Founded in 1997 and based in Cary, North Carolina, the company was originally named SimShop, Inc. before rebranding in 1999. Net32 aims to empower dentists to take control of their expenses and improve their financial performance by offering competitive pricing and a comprehensive selection of dental products.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.